Biofrontera Bioscience GmbH

Patent Disputes Highlight Innovation Challenges in Photodynamic Therapy and Genomic Sequencing Technologies

- The Patent Trial and Appeal Board ruled that Sun Pharmaceutical's patent claims for an adjustable illuminator used in photodynamic therapy are unpatentable as obvious over existing prior art. - Biofrontera companies successfully challenged Sun Pharmaceutical's illumination device patent, which relates to uniform light distribution for treating conditions like actinic keratosis. - In a separate case, Illumina successfully invalidated Molecular Loop Innovations' patent claims for nucleic acid template integrity methods in multiplex sequencing reactions. - These patent decisions underscore ongoing intellectual property challenges in medical device and genomic sequencing technology development.